Merck says cholesterol drug failed to show benefit

December 20, 2012

Drugmaker Merck & Co. said it will not seek U.S. approval for its cholesterol drug Tredaptive and is recommending doctors abroad stop prescribing it to new patients, based on failed study results.

The drug is sold in about 40 countries in Europe and elsewhere but is not a major product for Merck. In the first three quarters of 2012 the drug posted $13 million in sales.

The company said Thursday that results from a 25,700-patient study showed that adding Tredaptive to traditional statin therapy did not lower the risk of heart attack, stroke and related problems. Patients taking the cholesterol combination pill were also more likely to suffer serious, non-fatal adverse events. The study compared 4-year outcomes for patients taking Tredaptive plus statin drugs, to those taking statins alone.

Statins are a class of drugs that have long been used to lower levels of LDL, or "bad," cholesterol and slightly raise levels of HDL, or "good," cholesterol in the blood.

Tredaptive is a combination pill made up of niacin, which boosts good cholesterol, and laropiprant, which reduces the facial flushing caused by niacin.

Cowen & Co. analyst Steve Scala noted that the current statin treatment is a "high bar for a trial to overcome due to the substantial risk reduction associated with these drugs." Scala said in a research note that the uncertainty around the Tredaptive results "had been a long-standing reason to avoid Merck shares."

The Food and Drug Administration rejected Tredaptive in 2008 pending the more information about the drug's effects on the heart.

Company shares fell $1.03, or 2.4 percent, to $42.63 in morning trading.

Explore further: FDA panel to weigh revoking key use of Abbott drug

shares

Related Stories

FDA approves first diabetes-cholesterol combo pill

October 7, 2011

(AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.

FDA adds new safety information to statin drugs

February 28, 2012

(AP) -- Federal health officials are adding new safety warnings about risks of memory loss and elevated blood sugar to statins, a widely prescribed group of cholesterol-lowering medications.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.